MATTHEW BOLTON: Open Payments
NPI 1891163598 · HATTIESBURG, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$446 in 19 payments from 7 companies in 2025. Trend: 2023 $811 · 2024 $380 · 2025 $446
Food & beverage: $446
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 10 | $211 |
| GENZYME CORPORATION | 1 | $98 |
| Amgen Inc. | 3 | $46 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $34 |
| Corcept Therapeutics | 1 | $22 |
| Insulet Corporation | 1 | $19 |
| Novo Nordisk Inc | 1 | $16 |
Products named: QULIPTA, DUPIXENT, CAPLYTA, OTEZLA, Korlym, VRAYLAR, Omnipod, REPATHA.
Industry payments across MS — which companies pay providers there.
